

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Alvar Agusti

Member of: BoD, ScC

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
GSK	x	x			
AZ	x	x			
Menarini	x	x			
Chiesi	x	x			
Sanofi	x				
Nuvaira		x			
Zambon		x			

No SHARES

No Tobacco industry relationship

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Antonio Anzueto MD

Member of: Scientific Committee

Are there any relevant financial interests to disclose? (Yes)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
GlaxoSmithKline		X			Advisory Board, speaker
Theravance		X			Advisory Board, speaker
Boehringer-Ingelheim		X			Advisory Board, speaker
Mylan		X			Advisory Board, speaker
Novartis		X			Advisory Board
Grifols		X			Advisory Board, speaker
Sunovion Pharmaceutical		X			Advisory Board, speaker
Verona Pharmaceutical		X			Advisory Board
Chiessi Pharma.		X			Advisory Board

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Peter Barnes

Member of: GOLD Scientific Committee 2019

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca	Yes	Yes	No	No	
GSK	No	Yes	No	No	
Boehringer Ingelheim	Yes	Yes	No	No	
Novartis	No	Yes	No	No	
Teva	No	Yes	No	No	
Pieris	No	Yes	No	No	
Heptaris	yes	No	No	No	
No shares					

GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST



Name: RICHARD BEASLEY

Member of: GOLD BOARD OF TRUSTEES

Are there any relevant financial interests to disclose? (Yes or No in each box) ✓

Asuna Zeneca	✓	✓			
Glaxo Smith Kline	✓	✓			
Genentech	✓				
Avillion		✓			
Meravance		✓			
Fisher & Paykel Healthcare	✓				

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Jean Bourbeau

Member of: Scientific Committee Global Initiative for COPD

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
CIHR	Yes				
Canadian Respiratory Research Network (CRRN)	Yes				
Canadian Thoracic Society		Yes			Consultant/Lecture
CHEST		Yes			Consultant/Lecture
Foundation of the MUHC	Yes				
Aerocrine	Yes				
AstraZeneca	Yes	Yes			Advisor/Lecture
Boehringer Ingelheim	Yes	Yes			Advisor/Lecture
Grifols	Yes	Yes			Advisor/Lecture
GlaxoSmithKline	Yes	Yes			Advisor/Lecture
Novartis	Yes	Yes			Advisor/Lecture
Trudell	Yes	Yes			Advisor/Lecture

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Bartolome Celli

Member of: GOLD Executive Committee

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Astra Zeneca		Yes			Grant to institution
Boehringer Ingelheim		Yes			Consulting Fee
Novartis		Yes			Consulting Fee
Glaxo Smith Kline		Yes			Consulting Fee
Medimmune		Yes			Consulting Fee
Sanofi-Aventis		Yes			Consulting Fee
Chiesi		Yes			Consulting Fee
Menarini		Yes			Consulting Fee
Pulmonx		Yes			Consulting Fee

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Rongchang Chen

Member of: Director Borad

Are there any relevant financial interests to disclose? (Yes or No in each box)

Yes.

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
GSK	✓				
Astra-Zeneca	✓	✓			Speaker fee
Philips-Respironics	✓	✓			Speaker fee
Incentive Co	✓				Speaker fee

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Gerard J. Criner, MD

Member of: GOLD BoD

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
ALung Technologies, Inc.	Yes	No	No	No	
American College of Radiology	Yes	No	No	No	
American Lung Association	Yes	No	No	No	
Amgen	No	Yes	No	No	
AstraZeneca	Yes	Yes	No	No	
BioScale, Inc.	Yes	No	No	No	
Boehringer Ingelheim	Yes	Yes	No	No	
BREATH Therapeutics, Inc.	Yes	No	No	No	
Broncus Medical	No	Yes	No	No	
COPD Foundation	Yes	No	No	No	
Coridea/ZIDAN	Yes	No	No	No	
CSA Medical	No	Yes	No	No	
Dr. Karen Burns, St. Michael's Hospital	Yes	No	No	No	
Eolo Medical	No	Yes	No	No	
Fisher & Paykel Healthcare Limited	Yes	No	No	No	
Galapagos NV	Yes	No	No	No	
Gala Therapeutics	No	Yes	No	No	
GlaxoSmithKline	Yes	Yes	No	No	
Helios Medical	No	Yes	No	No	
HGE Health Care Solutions	No	No	No	Yes	Ownership Interest
Lungpacer Medical, Inc.	Yes	No	No	No	
Merck	No	Yes	No	No	
Medtronic	No	Yes	No	No	
Mereo BioPharma	No	Yes	No	No	
National Heart, Lung, & Blood Institute (NHLBI)	Yes	No	No	No	
NGM Biopharmaceuticals	No	Yes	No	No	
Nuvaira, Inc.	Yes	No	No	No	

Novartis	No	Yes	No	No	
Olympus	No	Yes	No	No	
PCORI	Yes	No	No	No	
Pulmonary Fibrosis Foundation	Yes	No	No	No	
PulmonX	Yes	Yes	No	No	
Respironics, Inc	Yes	Yes	No	No	
Respivant Sciences	Yes	Yes	No	No	
Spiration, Inc.	Yes	No	No	No	
Steward St. Elizabeth's Medical Center of Boston, Inc.	Yes	No	No	No	
The Implementation Group	No	Yes	No	No	
Verona Pharma	No	Yes	No	No	
Veracyte, Inc.	Yes	No	No	No	

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: David Halpin

Member of: Board of Directors & Science Committee

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Comments:
Boehringer Ingelheim		Y	Y		
Chiesi Pharmaceuticals		Y			
GSK		Y			
Novartis		Y	Y		
Pfizer		Y			

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: MeiLan Han

Member of: GOLD SC

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
GSK		x			
BI		x			
AZ		x			
Mylan		x			
Merck					
Sanofi				x	Investigator for a Sanofi sponsored clinical trial, funds paid to institution
Novartis				x	Drug supply to support NIH funded clinical trial
Sunovion				x	Research support for clinical trial

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL**



INTEREST

Name: Maria Victorina Lopez Varela

Member of: Board Directors

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Boehringer Ingelheim	No	Yes	No	No	Conference
AstraZeneca	No	Yes	No	No	Project Steering Committee

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Fernando Martinez

Member of: GOLD SC

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca	X (academic productivity)	X (honoraria)	X (travel support)		COPD ad boards, and study steering committee
Boehringer Ingelheim		X (honoraria)	X (travel support)		ERS COPD presentation
ProTERRIXBio	X (academic productivity)				COPD advisor – supporting NIH cohort study
Gala					COPD Ad board
GlaxoSmithKline	X (academic productivity)	X (honoraria)	X (travel support)		COPD ad boards, and study steering committee and DSMB
Teva		X (honoraria)	X (travel support)		COPD ad board
UpToDate		X (honoraria)			COPD CME

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Maria Montes de Oca

Member of: Scientific Committee and Board of Directors

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca	No	Yes	No	No	Speaker committee fees
Boehringer Ingelheim	No	Yes	No	No	Speaker fees

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE
DISCLOSURE OF INTEREST
FOR THE PERIOD 01/01/2019 to 31/12/2019**

Name: Kevin Mortimer

Member of
GOLD BOD

Are there any relevant financial interests to disclose? Yes

Research grants:

- 2015 **Medical Research Council Doctoral Training Partnership.** Biagini G, Mortimer_K (co-lead) and Diggle P. **£1.3m.** Translational and Quantitative Skills Doctoral Training Partnership in Global Health
- 2016 **Medical Research Council.** Mortimer_K (PI). **£606,000.** Lung Health in Africa across the life course
- 2017 **National Institute for Health Research.** Squire SB, Mortimer K (co-I) et al. **£7m.** NIHR Global Health Research Unit on Lung Health and Tuberculosis in Africa at LSTM
- 2017 **Medical Research Council.** Biagini G, Mortimer_K (co-lead) and Diggle P. **£257,469.** Liverpool School of Tropical Medicine and Lancaster University NPIF Studentships
- 2017 **Medical Research Council Skills Development Fellowship Programme.** Mortimer_K (PI). **£580k.** Translational and Quantitative Skills Development Fellowships in Global Health
- 2017 **Medical Research Council NPIF Skills Development Fellowship.** Mortimer_K (PI). **£286,000.** Translational and Quantitative NPIF Skills Development Fellowship in Global Health
- 2017 **Medical Research Council.** Allen S (PI), Mortimer_K (co-I) et al. **£218,002.** Improving the survival, growth and developmental of low birth weight newborns through better nutrition
- 2018 **Medical Research Council.** Biagini G, Mortimer_K (co-lead) and Diggle P. **£188,132.** Liverpool School of Tropical Medicine and Lancaster University NPIF Studentships
- 2018 **National Institute for Health Research.** Grigg J, Mortimer K (co-I) et al. **£2m.** NIHR Global Health Research Unit on improving asthma outcomes in African children at Barts and The London Queen Mary's School of Medicine and Dentistry
- 2018 **Wellcome Trust** Clinical PhD. Awarded to Sepedeh Saleh. Mortimer_K (primary supervisor). **£455,000.** A new approach to air pollution in peri-urban Malawi.
- 2018 **The Academy of Medical Sciences.** Lesosky M (PI) and Mortimer_K (co-I). **£92.6k.** Newton Advanced Fellowship: Biostatistical Methods for Bayesian Analysis of Multilevel Models of Lung Health in Africa.
- 2018 **Medical Research Council and Kenya National Research Fund Newton-Utafiti.** Mortimer_K and Muhwa C (co-PIs). **£715k.** Non-communicable lung disease in Kenya: from burden and early life determinants to participatory inter-disciplinary solutions.
- 2018 **Medical Research Council Skills Development Fellowship Programme.** Mortimer_K (PI). **£580k.** Translational and Quantitative Skills Development Fellowships in Global Health

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
International Union against Tuberculosis and lung disease (The Union)		X			KM is Director of Lung Health for The Union
AstraZeneca		X			Advisory board fee

TOBACCO INDUSTRY FUNDING

x I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature 

Date: 09/02/2020

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Alberto Papi

Member of: GOLD SC

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca	Yes	Yes	No	No	
Boehringer Ingelheim	Yes	Yes	No	No	
Chiesi Farmaceutici	Yes	Yes	No	No	
GlaxoSmithKline	Yes	Yes	No	No	
Mundipharma	No	Yes	No	No	
TEVA	Yes	Yes	No	No	
Novartis	Yes	Yes	No	No	
Zambon	No	Yes	No	No	
Sanofi	Yes	Yes	No	No	
Menarini	No	Yes	No	No	
Elpen Pharmaceutical	No	Yes	No	No	
MSD	No	Yes	No	No	
Avillion	No	Yes	No	No	

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Ian Pavord

Member of: GOLD Science Committee

Are there any relevant financial interests to disclose?

In the last 5 years IDP has received speaker's honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva.


2/3/19

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Nicholas Roche

Member of: GOLD Science Committee

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca		Yes			
Boehringer Ingelheim	Yes	Yes			
Chiesi		Yes			
Novartis	Yes	Yes			
Pfizer	Yes	Yes			
Sanofi		Yes			
Sandoz		Yes			
Mundipharma		Yes			
GSK		Yes			
3M		Yes			
AstraZeneca		Yes			

GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD) DISCLOSURE OF FINANCIAL INTEREST



Name: Don D. Sin

Member of: GOLD Scientific Committee

Are there any relevant financial interests to disclose? (Yes in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca	Yes	Yes			
Boehringer Ingelheim		Yes			
Nuvaira		Yes			

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Dave Singh

Member of: GOLD Science Committee

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca		Y			
Boehringer Ingelheim		Y			
Chiesi		Y			
Cipla		Y			
Genentech		Y			
GlaxoSmithKline		Y			
Glenmark		Y			
Gossamerbio		Y			
Menarini		Y			
Mundipharma		Y			
Novartis		Y			
Peptinnovate		Y			
Pfizer		Y			
Pulmatrix		Y			
Theravance		Y			
Verona		Y			

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: R.Stockley

Member of: Scientific committee

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Mereo biopharma	yes	yes	no	Travel fee to FDA	CI for phase 2 study. Therapeutic in vitro studies
CSL Behring	no	yes	no		Steering board and lecture fees
Kamada	no	yes	no		DSMB for phase 3 study
Vertex	no	yes	no		Steering board
Z factor	no	Yes	no		Steering board
Alpha one Foundation	yes	no	no	Travel fee	
GSK	no	no	no	Lecture fee	

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Claus Vogelmeier

Member of: GOLD BoD

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Boehringer	<input type="checkbox"/>	x			
CSL Behring		x			
Chiesi		X			
GlaxoSmithKline	<input type="checkbox"/>	X			
Grifols	<input type="checkbox"/>	X			
Menarini		X			
Novartis	<input type="checkbox"/>	X			
AstraZeneca	<input checked="" type="checkbox"/>	x			
Nuvaira		x			

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Wisia Wedzicha

Member of: GOLD Science Committee

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
GSK	Yes				
Astra Zeneca	Yes				
Chiesi	Yes				
Boehringer	Yes				
Novartis	Yes				